Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;80(6):1811-1814.
doi: 10.1111/all.16610. Epub 2025 Jun 10.

Dupilumab and Blood Eosinophilia: A Disease-Specific Phenomenon?

Andrea Portacci  1 , Remo Poto  2   3 , Gilda Varricchi  2   4 , Giovanna Elisiana Carpagnano  1
Affiliations

Dupilumab and Blood Eosinophilia: A Disease-Specific Phenomenon?

Andrea Portacci et al. Allergy. 2025 Jun.
No abstract available

Keywords: COPD; CRSwNP; Dupilumab; asthma; atopic dermatitis; eosinophilic esophagitis; hypereosinophilia.

PubMed Disclaimer

Conflict of interest statement

Andrea Portacci reported payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from Astrazeneca, GlaxoSmithKline, Chiesi, Sanofi. Remo Poto reported personal fees from Astrazeneca and GSK. Gilda Varricchi reported research support from Astrazeneca. Giovanna Elisiana Carpagnano reported grants or contracts from Astrazeneca, Chiesi, GlaxoSmithKline, Sanofi, Grifols; payment or honoraria for lectures, presentations, speakers, bureaus, manuscript writing, or educational events from Astrazeneca, GlaxoSmithKline, Sanofi; support for attending meetings and/or travel from Astrazeneca, Menarini, Chiesi.

Figures

FIGURE 1
FIGURE 1
Possible mechanisms explaining the absence of transient blood eosinophilia in patients with COPD and EoE during dupilumab treatment. IL‐33 and IL‐18 could empower eosinophils maturation and migration from blood vessels to the airways. IL‐18 can also induce vascular cell adhesion molecule 1 (VCAM‐1) expression and group 2 innate lymphoid cells (ILC2) shift towards ILC1, reducing eosinophils bloodstream accumulation. Figure created using Biorender (https://biorender.com/).
See this image and copyright information in PMC

References

    1. McCann M. R., Kosloski M. P., Xu C., Davis J. D., and Kamal M. A., “Dupilumab: Mechanism of Action, Clinical, and Translational Science,” Clinical and Translational Science 17, no. 8 (2024): e13899, 10.1111/CTS.13899. - DOI - PMC - PubMed
    1. Wechsler M. E., Klion A. D., Paggiaro P., et al., “Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis,” Journal of Allergy and Clinical Immunology. In Practice 10, no. 10 (2022): 2695–2709, 10.1016/J.JAIP.2022.05.019. - DOI - PubMed
    1. Castro M., Corren J., Pavord I. D., et al., “Dupilumab Efficacy and Safety in Moderate‐To‐Severe Uncontrolled Asthma,” New England Journal of Medicine 378, no. 26 (2018): 2486–2496, 10.1056/NEJMOA1804092. - DOI - PubMed
    1. Ryser F. S., Yalamanoglu A., Valaperti A., et al., “Dupilumab‐Induced Eosinophilia in Patients With Diffuse Type 2 Chronic Rhinosinusitis,” Allergy 78, no. 10 (2023): 2712–2723, 10.1111/all.15844. - DOI - PubMed
    1. Li J., Wang Q., Zhang Q., et al., “Higher Blood Vascular Cell Adhesion Molecule‐1 Is Related to the Increased Risk of Cardiovascular Events in Chronic Obstructive Pulmonary Disease,” International Journal of COPD 15 (2020): 2289–2295, 10.2147/COPD.S264889. - DOI - PMC - PubMed

LinkOut - more resources